Sanadihii la soo dhaafay, warshadaha ogaanshaha gudaha gudaha vitro (IVD) ayaa si degdeg ah u koray.Marka loo eego xogta ay soo saartay Evaluate MedTech, laga bilaabo 2014 ilaa 2017, qiyaasta iibka suuqa caalamiga ah ee warshadaha IVD ayaa kordhay sanadba sanadka ka dambeeya, laga bilaabo $49 bilyan 900 milyan 2014 ilaa $52 bilyan 600 milyan ee 2017, iyada oo heerka kobaca sanadlaha ah ee isku dhafan ee 1.8%;sanadka 2024, cabirka iibka suuqa waxa la filayaa inuu gaadho $79 bilyan 600 milyan, laga bilaabo 2017 ilaa 2024Xaaladdan oo kale, baahida caafimaad ee sii kordheysa iyo heerarka codsiga warshadaha ayaa sidoo kale soo bandhigay shuruudo cusub oo loogu talagalay alaabada iyo teknoolojiyadda IVD.Toban sano ka dib horumarinta madax-bannaanida ee "Tiknoolajiyada Chemiluminescence ee iftiinka Lica", sida habka cusub ee chemiluminescent immunoassay, ogaanshaha Kemei wuxuu si hal-abuur leh u qaataa nidaamka falcelinta isku midka ah iyo nano-farsamooyinka sare ee farsamada, siinta xal cusub oo loogu talagalay shaybaarada caafimaad ee badan.Sida laga soo xigtay xogta dadweynaha, oo ku saabsan berrinka chemiluminescence immunodiagnosis ee Shiinaha, natiijooyinka degenaansho wanaagsan ayaa lagu gaaray goobta tallaalka difaaca jirka ee dhexdhexaadka ah iyo kuwa hooseeya.Si kastaba ha ahaatee, suuqa kiimikada-dhamaadka sare ee Shiinaha, warshadeeyayaasha la soo dejiyo ayaa wali ku jira in ka badan 80% saamiga suuqa.Kuwaas waxaa ka mid ah, Abbott, Roche, Beckman iyo Siemens ayaa ah qiyaastii 70% saamiga suuqa.Si kastaba ha ahaatee, iyada oo la hagaajinayo heerka isticmaalka caafimaadka ee Shiinaha, horumarinta dib u habaynta nidaamka caafimaadka, iyo taageerada xooggan ee siyaasadaha warshadaha qaranka, waxaan diiradda saarnay horumarinta reagents ogaanshaha vitro, waxaana rajeyneynaa inaan kula shaqeyno.